Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine

Research Institute for Biological Safety Problems

Status and phase: Completed; Phase 2; Phase 1

Conditions: Vaccine Adverse Reaction; SARS-CoV Infection; Covid19

Treatments: Biological: QazCovid-in® - COVID-19 inactivated vaccine; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04530357

QAZCOV-I/II-01/2020

Details and patient eligibility

About

Randomized, blind, placebo-controlled phase- i study and randomized, open phase phase-ii study of QAZCOVID-IN®- COVID-19 inactivated vaccine in healthy adult volunteers from 18 years old and elder

Full description

Purpose of the Phase-I clinical study Evaluation of the safety,acceptability and immunogenicity of QazCovid-in®-COVID-19 inactivated vaccine when administeredtwice in healthy volunteers aged 18-50 years.

Purpose of the Phase-II clinical study Evaluation of the safety and immunogenicity of QazCovid-in® - COVID-19 inactivated vaccine with single and dual use in healthy volunteers aged 18 and above.

Enrollment: 244 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Availability of signed and dated informed consent of the volunteer to participate in the study.
• Healthy male and female volunteers aged 18-50 and 50 and above.
• Ability and voluntary desire to independently keep records in the Self-Observation Diary, as well as to carry out all the repeated visits provided for in the study for control medical observation.
• The voluntary desire of females to use methods of reliable contraception throughout the entire period of their participation in the study.
• Negative results for IgM and IgG antibodies to SARS-CoV-2.
• Absence of COVID-19 diagnosis in history.
• Absence in the last 14 days of close contact with persons suspected of being infected with SARS-CoV-2, or persons whose diagnosis of COVID-19 has been confirmed with laboratory.
• Negative test results for human immunodeficiency virus (HIV), hepatitis B and hepatitis C.

Exclusion criteria

• Aggravated allergic history, drug intolerance, including hypersensitivity to any of the components of the study drug, as well as a history of serious adverse events during vaccine administration (such as allergic reactions, respiratory failure, angioedema, abdominal pain).
• Acute illness with fever (body temperature ≥37.1°C) at the time of screening/randomization.
• Chronic alcohol and/or drug use in history.
• Clinically significant deviations from normal values during laboratory and/or imaging at screening.
• Women with a positive urine pregnancy test.
• Simultaneous treatment with immunosuppressive drugs, including corticosteroids (2 weeks) 4 weeks prior to study drug administration.
• Acute or chronic clinically significant lesions of the lungs, cardiovascular system, gastrointestinal tract, liver, blood system, skin, endocrine, neurological and psychiatric diseases or impaired renal function (asthma, diabetes, thyroid disease, arrhythmia, myocardial infarction, severe hypertension not controlled by drugs, etc.), identified based on medical history, physical examination or clinical laboratory tests that, according to the researcher, may affect the study result.
• Disruption of platelets or other blood clotting disorders, which may cause contraindications to intramuscular administration.
• Leukemia or neoplasm in history.
• Persons with autoimmune diseases.
• Volunteers who received antiviral drugs, immunoglobulin's or blood transfusions or any other investigational drug within 4 weeks prior to study drug administration;
• Volunteers who received anti-inflammatory drugs 2 days before study drug administration;
• Participation in any other clinical research within the last 3 months.
• Volunteers with a concern that they will not comply with the study requirements, or persons with severe physical or mental disabilities that may affect the completion of the study.
• Voluntary refusal to study.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

244 participants in 6 patient groups, including a placebo group

Phase 1 Adult-vaccine (A Sample, blind study)

Experimental group

Description:

Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml

Treatment:

Biological: QazCovid-in® - COVID-19 inactivated vaccine

Phase 1 Adult-Placebo (A Sample, blind study)

Placebo Comparator group

Description:

Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml

Treatment:

Other: Placebo

Phase 2 Adult-Vaccine, twice vaccination (An Open study)

Experimental group

Description:

Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml

Treatment:

Biological: QazCovid-in® - COVID-19 inactivated vaccine

Phase 2 Elderly-Vaccine, twice vaccination (An Open study)

Experimental group

Description:

Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml

Treatment:

Biological: QazCovid-in® - COVID-19 inactivated vaccine

Phase 2 Adult-Vaccine, single vaccination (An Open study)

Experimental group

Description:

Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder

Treatment:

Biological: QazCovid-in® - COVID-19 inactivated vaccine

Phase 2 Elderly-Vaccine, single vaccination (An Open study)

Experimental group

Description:

Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml

Treatment:

Biological: QazCovid-in® - COVID-19 inactivated vaccine